Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$3.04 +0.7%	$4.58	$2.90 ▼ $135.54	$2.42M	-0.28	456,469 shs	168,566 shs
ATNF 180 Life Sciences	$0.86 -1.8%	$1.01	$0.66 ▼ $17.75	$5.01M	0.23	795,320 shs	18,806 shs
BPTSY Biophytis	$1.38	$2.15	$1.38 ▼ $8.00	$484K	0.84	2,149 shs	N/A
SXTP 60 Degrees Pharmaceuticals	$2.07 -4.2%	$2.56	$1.41 ▼ $35.99	$3.18M	2.88	576,087 shs	657,142 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	0.00%	-5.33%	-14.20%	-66.78%	-91.59%
ATNF 180 Life Sciences	0.00%	-11.99%	-23.47%	-22.12%	-46.34%
BPTSY Biophytis	0.00%	0.00%	-33.65%	-58.93%	-81.28%
SXTP 60 Degrees Pharmaceuticals	0.00%	-5.26%	-8.86%	+22.03%	+61.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALZN Alzamend Neuro	2.3747 of 5 stars	3.5	2.0	0.0	0.0	1.1	4.2	0.0
ATNF 180 Life Sciences	0.353 of 5 stars	0.0	4.0	0.0	0.0	0.6	0.0	0.6
BPTSY Biophytis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.9411 of 5 stars	3.3	5.0	0.0	0.0	1.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	3.00	Buy	$180.00	5,821.05% Upside
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
BPTSY Biophytis	0.00	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	238.16% Upside

Current Analyst Ratings Breakdown

Latest BPTSY, SXTP, ATNF, and ALZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/8/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/8/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	($31.66) per share	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
BPTSY Biophytis	N/A	N/A	N/A	N/A	($16.18) per share	N/A
SXTP 60 Degrees Pharmaceuticals	$665.45K	4.58	N/A	N/A	($6.38) per share	-0.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$9.95M	N/A	0.00	N/A	N/A	N/A	-497.73%	-147.21%	7/29/2025 (Estimated)
ATNF 180 Life Sciences	-$6.17M	N/A	0.00	∞	N/A	N/A	-147.32%	-76.99%	8/11/2025 (Estimated)
BPTSY Biophytis	-$18.43M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-1,947.30%	N/A	-174.90%	8/13/2025 (Estimated)

Latest BPTSY, SXTP, ATNF, and ALZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	ATNF 180 Life Sciences	N/A	-$0.67	N/A	-$0.67	N/A	N/A
5/15/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	-$1.56	-$0.25	-$1.56	$0.15 million	$0.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
BPTSY Biophytis	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	5.44	5.44
ATNF 180 Life Sciences	N/A	1.02	1.02
BPTSY Biophytis	N/A	0.41	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	3.14	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
ATNF 180 Life Sciences	4.07%
BPTSY Biophytis	0.05%
SXTP 60 Degrees Pharmaceuticals	7.96%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	30.21%
ATNF 180 Life Sciences	0.17%
BPTSY Biophytis	3.70%
SXTP 60 Degrees Pharmaceuticals	10.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	800,000	559,000	No Data
ATNF 180 Life Sciences	7	5.70 million	5.69 million	No Data
BPTSY Biophytis	30	351,000	338,000	N/A
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	1.32 million	Not Optionable

BPTSY, SXTP, ATNF, and ALZN Headlines

Recent News About These Companies

60 Degrees Pharmaceuticals (NASDAQ:SXTP) Cut to Sell at Wall Street Zen

June 14, 2025 | americanbankingnews.com

60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives "Sell (E+)" Rating from Weiss Ratings

June 12, 2025 | americanbankingnews.com

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 Shares

June 6, 2025 | insidertrades.com

60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026

June 5, 2025 | nasdaq.com

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

June 4, 2025 | globenewswire.com

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

June 3, 2025 | globenewswire.com

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025 | globenewswire.com

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

April 22, 2025 | globenewswire.com

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

April 10, 2025 | insidermonkey.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

April 8, 2025 | globenewswire.com

60 Degrees Pharmaceuticals, Inc.

April 4, 2025 | uk.investing.com

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 21, 2025 | accessnewswire.com

60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split

February 20, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing Requirements

February 20, 2025 | quiverquant.com

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

February 20, 2025 | globenewswire.com

60 Degrees says FDA does not object to tafenoquine import plan

February 11, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Receives FDA Approval for Importing KODATEF® as Preemptive Measure for ARAKODA® Supply Stability

February 11, 2025 | quiverquant.com

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

February 11, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY, SXTP, ATNF, and ALZN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$3.04 +0.02 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$3.05 +0.01 (+0.33%)

As of 07:59 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

180 Life Sciences NASDAQ:ATNF

$0.86 -0.02 (-1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.87 +0.00 (+0.21%)

As of 06:09 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Biophytis NASDAQ:BPTSY

$1.38 0.00 (0.00%)

As of 06/18/2025

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$2.07 -0.09 (-4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$2.02 -0.05 (-2.66%)

As of 07:39 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time